Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Operating Leases (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Operating Leases for 5 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 25.22% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 25.22% year-over-year, with the annual reading at $7.6 million for FY2025, 25.22% up from the prior year.
  • Operating Leases hit $7.6 million in Q4 2025 for Krystal Biotech, down from $9.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $9.7 million in Q2 2025 to a low of $3.2 million in Q1 2021.
  • Historically, Operating Leases has averaged $7.7 million across 5 years, with a median of $7.6 million in 2024.
  • Biggest five-year swings in Operating Leases: surged 188.45% in 2022 and later fell 26.18% in 2024.
  • Year by year, Operating Leases stood at $7.0 million in 2021, then grew by 5.57% to $7.4 million in 2022, then fell by 10.2% to $6.6 million in 2023, then decreased by 8.7% to $6.0 million in 2024, then grew by 25.22% to $7.6 million in 2025.
  • Business Quant data shows Operating Leases for KRYS at $7.6 million in Q4 2025, $9.5 million in Q3 2025, and $9.7 million in Q2 2025.